Willis Investment Counsel Buys 31,787 Shares of Zoetis Inc. $ZTS

Willis Investment Counsel boosted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 22.7% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 171,746 shares of the company’s stock after buying an additional 31,787 shares during the period. Willis Investment Counsel’s holdings in Zoetis were worth $12,342,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Brighton Jones LLC increased its position in Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock valued at $754,000 after acquiring an additional 2,978 shares during the last quarter. Empowered Funds LLC lifted its holdings in shares of Zoetis by 6.2% in the 1st quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after acquiring an additional 657 shares during the last quarter. Intech Investment Management LLC lifted its holdings in shares of Zoetis by 17.2% in the 1st quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock worth $1,374,000 after acquiring an additional 1,224 shares during the last quarter. Sivia Capital Partners LLC boosted its stake in shares of Zoetis by 73.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock worth $522,000 after purchasing an additional 1,422 shares during the period. Finally, Glenview Trust co boosted its stake in shares of Zoetis by 11.8% during the 2nd quarter. Glenview Trust co now owns 4,780 shares of the company’s stock worth $745,000 after purchasing an additional 506 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Zoetis Trading Down 2.9%

ZTS stock opened at $73.64 on Friday. The company has a market capitalization of $30.43 billion, a PE ratio of 12.13, a P/E/G ratio of 1.31 and a beta of 0.74. Zoetis Inc. has a 12 month low of $71.45 and a 12 month high of $160.48. The firm’s 50-day moving average is $76.30 and its 200 day moving average is $99.01. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, beating analysts’ consensus estimates of $1.85 by $0.02. The company had revenue of $2.47 billion during the quarter, compared to analyst estimates of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The firm’s revenue for the quarter was down .2% on a year-over-year basis. During the same quarter last year, the business posted $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, research analysts anticipate that Zoetis Inc. will post 6.19 EPS for the current year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be paid a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s payout ratio is currently 34.93%.

Wall Street Analysts Forecast Growth

ZTS has been the topic of several analyst reports. BNP Paribas Exane cut their price target on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a report on Tuesday. Morgan Stanley set a $85.00 target price on Zoetis in a research report on Friday, August 7th. JPMorgan Chase & Co. cut their target price on Zoetis from $130.00 to $115.00 and set an “overweight” rating on the stock in a research note on Friday, August 7th. William Blair reiterated a “market perform” rating on shares of Zoetis in a report on Thursday, August 6th. Finally, Barclays decreased their price target on Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 1st. Eight research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $109.62.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.